Mixed connective tissue disease (MCTD; Sharp syndrome)
Bedside summary
Overlap connective tissue disease defined by high-titre anti-U1-RNP antibody plus features of SLE, systemic sclerosis and polymyositis occurring together or sequentially. Classic triad/clues: Raynaud phenomenon, swollen ('puffy') hands/sausage digits, and anti-U1-RNP positivity, with arthritis, myositis, oesophageal dysmotility and sclerodactyly. Course variable; pulmonary arterial hypertension is the leading cause of death. May evolve into a dominant single CTD (often SSc or SLE) over time. Treatment follows the dominant organ involvement.
Red flags
- Exertional breathlessness/syncope/right heart strain — pulmonary arterial hypertension (leading cause of death)
- Progressive proximal weakness + raised CK — significant myositis
- Dysphagia/aspiration — oesophageal dysmotility
- New hypertension + AKI — scleroderma-overlap renal crisis (ACE inhibitor)
- High anti-RNP with evolving diffuse skin — transformation to systemic sclerosis
Assessment
Differential diagnosis
- SLE (anti-dsDNA/Sm, nephritis more prominent, low complement)
- Systemic sclerosis (anticentromere/Scl-70, more fibrosis)
- Polymyositis/dermatomyositis (myositis-specific antibodies)
- Undifferentiated connective tissue disease (features insufficient for a defined CTD)
- Rheumatoid arthritis overlap (anti-CCP positive, erosive)
Investigations
- ANA (high-titre speckled) + anti-U1-RNP (hallmark; required for diagnosis)
- Anti-dsDNA/anti-Sm (usually negative — their presence suggests SLE instead)
- CK, LDH, aldolase (myositis); EMG/MRI/muscle biopsy if weakness
- FBC, U&E, urinalysis (cytopenias, renal involvement less common than SLE)
- Echocardiography + NT-proBNP annually (pulmonary hypertension screen) + PFTs/HRCT for ILD
- Nailfold capillaroscopy (SSc pattern); oesophageal studies if dysphagia
Management
- Confirm anti-U1-RNP positivity with compatible clinical overlap features; exclude a dominant single CTD
- Treat by dominant manifestation — there is no MCTD-specific regimen
- Arthralgia/arthritis + fatigue: hydroxychloroquine +/- NSAIDs; methotrexate for persistent arthritis
- Raynaud: cold avoidance + calcium-channel blocker (see Raynaud entry); vasodilators for digital ulcers
- Myositis: glucocorticoids + steroid-sparing agent (methotrexate/azathioprine); IVIG if severe
- Serositis/moderate systemic flare: glucocorticoids + immunosuppressant (azathioprine/mycophenolate)
- Screen and aggressively manage pulmonary arterial hypertension and ILD (refer PH/respiratory centre)
- Long-term monitoring for evolution into SSc/SLE and for PAH — leading cause of mortality
Drugs & doses
Disposition
Complications & pitfalls
- Pulmonary arterial hypertension (major mortality driver)
- Interstitial lung disease
- Inflammatory myopathy, oesophageal dysmotility/aspiration
- Evolution to a dominant CTD (SSc or SLE)
- Digital ischaemia from Raynaud
Exam pearls
- Anti-U1-RNP is the defining antibody; absence of anti-dsDNA/Sm helps separate MCTD from SLE.
- Pulmonary arterial hypertension — not renal disease — is the leading cause of death; screen with annual echo + NT-proBNP.
- MCTD tends to be more steroid-responsive than pure SSc, but watch for renal-crisis risk if sclerodermatous.
- 'Puffy hands' + Raynaud + high-titre speckled ANA should prompt anti-RNP testing.
- Treat the dominant organ phenotype — there is no single MCTD protocol.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.